Episode 46: Can We Achieve Clinical Remission In Asthma?

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!

For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Reviewed by Iris Otani

Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.

Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839.

Clinical Remission in a Real-World Severe Asthma Registry

Reviewed by Tim Chow

Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.

McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453.

More Evidence Against Using Corticosteroids for Anaphylaxis

Reviewed by Iris Otani

Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data.

Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113.

Please rate our podcast on Apple podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: [e-mail]

You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

 

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)